Related Experiment Video
Updated: Jun 9, 2025
07:12
Establishment of a Simple and Effective Rat Model for Intraoperative Parathyroid Gland Imaging
Published on: August 17, 2022
3.3K
Parathyroid carcinoma: a tertiary centre's experience over 15 years.
Jeremy Wong1, Alfred Addison1, Ramez Nassif1
1Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, Norfolk, United Kingdom - Department of Ears, Nose and Throat.
The Journal of Laryngology and Otology
|October 23, 2024
Summary
Parathyroid carcinoma recurrence and metastasis are rare. Surgical excision is key, but hypercalcemia management and long-term monitoring are crucial for survival outcomes in these rare endocrine tumors.
Area of Science:
- Endocrinology
- Oncology
- Surgical Oncology
Background:
- Parathyroid carcinoma is a rare endocrine malignancy.
- Understanding its recurrence, metastasis, and survival is vital for patient management.
Purpose of the Study:
- To determine the recurrence rates, metastasis, and survival outcomes for patients with parathyroid carcinoma.
- To analyze treatment effectiveness and long-term prognosis.
Main Methods:
- Retrospective chart review of patients diagnosed with parathyroid carcinoma.
- Data collected from a UK tertiary center between January 2007 and December 2022.
Main Results:
- Fourteen patients with parathyroid carcinoma were identified, all treated with surgery.
- 100% presented with hypercalcemia; 14% had metastatic lesions.
- A single case (7%) of loco-regional recurrence was observed; 4 of 6 deaths were carcinoma-related.
Conclusions:
- Surgical excision is the primary treatment, requiring prior medical stabilization.
- Hypercalcemia is a major cause of mortality.
- While metastasis and recurrence were rare in this cohort, long-term monitoring of calcium and parathyroid hormone levels is essential.
